Revolutionizing Precision Medicine with Artificial Intelligence in 2023: A New Era of Patient Care

Variations in genes, environment, and lifestyle are taken into consideration by precision medicine, a method of providing treatment. It seeks to tailor medical care and prevention methods according to a patient's particular traits. One of the key tools in precision medicine is artificial intelligence (AI).

AI can help analyze large amounts of data from various sources, including genomics, electronic health records, and imaging. In addition to assisting in the prediction of illness risk, diagnosis, and treatment response, machine learning algorithms can spot patterns and relationships that may be challenging for people to see.

For example, AI can analyze a patient's genomic data to identify genetic variants that may increase the risk of developing certain diseases or affect their response to certain drugs. AI can also analyze imaging data to identify early signs of disease or track disease progression.

In addition to improving diagnosis and treatment, AI can also help accelerate drug development. By analyzing large datasets, AI can identify potential drug targets and predict how different drugs will affect different patient populations. While AI has the potential to revolutionize precision medicine, there are also challenges to overcome, such as data privacy and bias. Nevertheless, a lot of academics and medical specialists think that AI will become more crucial to the evolution of precision medicine.

A polygenic risk score (PRS) and an AI tool can measure the steps patients can take to lower their inherited risk of coronary artery disease, according to late-breaking clinical trial findings presented in March 2023 at the annual scientific meeting of the American College of Cardiology (ACC) and World Congress of Cardiology.
The Broad Institute and Fabric Genomics have introduced a brand-new genetic testing service. This new service offers clinical whole-genome sequencing (WGS) and variant interpretation for patients with genetic disorders. It costs $1,000 per sample and is available to healthcare providers and researchers who need clinical WGS and data interpretation. Customers can submit whole blood, saliva, or extracted DNA, which is then processed by the Broad's CLIA-licensed, CAP-accredited clinical sequencing facility once the test has been sequenced using the Illumina NovaSeq 6000 platform. A "healthy genome" option is not now offered by the service, but it might be in the future.
Agilent Technologies and PathAI are working together to create assays and provide anatomic pathology labs with PathAI's software and algorithms. The collaboration will deal with the creation of assays, such as digital pathology tests and companion diagnostics. Agilent will also distribute PathAI's software and algorithm to anatomic pathology labs under a global distribution agreement. The partnership brings together Agilent's assay development capabilities, PathAI's digital algorithm expertise, and Agilent's workflow expertise. Financial details of the deal were not disclosed.
In an effort to better understand how whole-genome sequencing (WGS) may affect cardiovascular disease, Illumina and Henry Ford Health have teamed up. Implementation and clinical studies to examine the use of WGS tests in cardiac care will be carried out by Henry Ford's precision medicine and genomic medicine centres, both of which are situated in Detroit. Illumina's WGS-based test will be used in the 1,500 patient CardioSeq research to produce a "comprehensive cardiovascular genomic profile." The collaboration could support the application of WGS for the prevention and treatment of cardiovascular disease. The deal's financial specifics were kept confidential. In 2024, the study is anticipated to be finished.

In the future, the use of AI in precision medicine will be ubiquitous and transformative. Patient data will be seamlessly integrated from multiple sources, including genomic data, electronic health records, wearable devices, and environmental sensors. These data will be quickly analysed by AI systems to find trends and forecast individual illness risk and treatment response. This will make it possible for medical professionals to create individualised treatment regimens that are catered to each patient's particular needs, improving outcomes and cutting healthcare expenditures. AI-powered virtual assistants will be available to patients 24/7, providing real-time monitoring and support, and enabling proactive interventions to prevent disease progression. BioIntel360 expects that as the field of precision medicine continues to evolve, AI will undoubtedly play a pivotal role in accelerating progress and improving patient outcomes.